ASTRAZENECA CAMCAR, S.A., a division of AstraZeneca focused in Central American and Caribbean countries, has partnered with Cancer Genetics Inc. to provide biomarker-based diagnostic testing for cancer.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
